Approaches to Bridging Therapy During the CAR T Manufacturing Process

Opinion
Video

Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content